Detection of Human Immunodeficiency Virus Type 1 (HIV-1) in Vaginocervical Secretions: Correlation With Clinical Status, Virologic and Immunologic Parameters, and the Presence of Other Infections
Completed
Conditions studied: HIV Infections
In brief
To correlate HIV-1 viral load in vaginocervical secretions (VCS), as measured by culture and nucleic acid detection, with that found in peripheral blood and HIV clinical status. To determine whether systemic and local HIV specific antibody influences the quality and type of virus isolated from VCS. To ascertain whether the presence of specific infectious agents (e.g., HPV, HSV, CMV, etc.) influences the amount and type of virus isolated from VCS. Predictors for the development of the acquired immunodeficiency syndrome (AIDS) in HIV infected individuals have been studied primarily among adult males and in selected small populations. Although many of these predictors may be relevant to women, HIV infection does manifest itself differently between the sexes. Therefore, it is important to study the spectrum of HIV disease in women and to identify unique and common markers, cofactors, and predictors of disease progression.
Key facts
- Study ID
- NCT00000858
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 350
- Last updated by the study team
- 2005-06-24
Who can join
Age: 18 and older, up to 45. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Patients must have:
- Premenopausal status.
- Intact uterus and cervix.
- Documented HIV infection.
- Current enrollment in a multisite longitudinal study, Women's Interagency HIV Study (WIHS).
- Required:
- Stable or no antiretroviral therapy within 1 month prior to study entry.
You may not qualify if…
- Concurrent Medication:
- Excluded:
- Antifungal or antimicrobial medication in the vagina.
- Prior Medication:
- Excluded:
- Antimicrobial or antifungal medications during the 48 hours prior to study entry.
- Use of spermicide or douche in the 48 hours prior to entry.
- Coital interaction during the 48 hours prior to study visit, as reported by subject and confirmed by a negative seminal fluid assay result.
Where it is running
- Univ of California / San Francisco — San Francisco, California, United States
- Georgetown Univ Med Ctr — Washington D.C., District of Columbia, United States
- SUNY / Health Sciences Ctr at Brooklyn — Brooklyn, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.